Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK [NYSE]
Merck & Co. Inc.
IndexDJIA S&P500 P/E14.09 EPS (ttm)4.10 Insider Own0.04% Shs Outstand2.84B Perf Week-1.42%
Market Cap163.91B Forward P/E15.16 EPS next Y3.81 Insider Trans-22.19% Shs Float2.84B Perf Month-1.27%
Income11.92B PEG2.94 EPS next Q0.75 Inst Own75.50% Short Float1.01% Perf Quarter1.32%
Sales42.24B P/S3.88 EPS this Y176.90% Inst Trans-0.37% Short Ratio2.52 Perf Half Y-1.65%
Book/sh17.08 P/B3.38 EPS next Y12.59% ROA11.70% Target Price63.77 Perf Year6.83%
Cash/sh5.54 P/C10.43 EPS next 5Y4.79% ROE24.80% 52W Range51.67 - 63.11 Perf YTD2.52%
Dividend1.80 P/FCF119.38 EPS past 5Y-6.30% ROI0.50% 52W High-8.49% Beta0.34
Dividend %3.12% Quick Ratio1.50 Sales past 5Y9.00% Gross Margin61.20% 52W Low11.76% ATR0.97
Employees70000 Current Ratio1.80 Sales Q/Q-7.40% Oper. Margin37.40% RSI (14)47.62 Volatility1.79% 1.66%
OptionableYes Debt/Eq0.44 EPS Q/Q876.90% Profit Margin28.20% Rel Volume0.75 Prev Close57.60
ShortableYes LT Debt/Eq0.38 EarningsApr 28 BMO Payout42.40% Avg Volume11.34M Price57.75
Recom2.50 SMA200.65% SMA50-1.80% SMA200-0.37% Volume8,513,229 Change0.26%
Apr-30-14Reiterated Argus Buy $62 → $66
Apr-11-14Reiterated MKM Partners Buy $64 → $70
Feb-05-14Reiterated Argus Buy $54 → $62
Jan-14-14Reiterated MKM Partners Buy $59 → $64
Jun-03-13Reiterated MKM Partners Buy $54 → $59
Apr-15-13Reiterated Barclays Overweight $45 → $60
Feb-04-13Reiterated MKM Partners Buy $51 → $52
Feb-04-13Reiterated Barclays Overweight $46 → $45
Nov-20-12Upgrade MKM Partners Neutral → Buy $47 → $51
Oct-17-12Reiterated MP Advisors Outperform $45 → $50
Jul-30-12Reiterated UBS Buy $45 → $50
Jul-13-12Upgrade MP Advisors Market Perform → Outperform $45
Feb-03-12Reiterated Barclays Capital Overweight $38 → $40
Feb-03-12Downgrade MKM Partners Buy → Neutral $42 → $40
Nov-29-11Initiated MKM Partners Buy $38
Sep-14-11Reiterated Barclays Capital Overweight $41 → $38
May-16-11Reiterated UBS Buy $40 → $42
Feb-04-11Reiterated UBS Buy $42 → $40
Jan-24-11Reiterated Deutsche Bank Buy $48 → $43
Jan-24-11Reiterated Barclays Capital Overweight $43 → $41
Mar-27-15 07:09PM  Lightning Round: Stay far away from this at CNBC
04:01PM  Pfizer: A Leading Pharmaceutical Company
02:40PM  Immune Design Starts Dosing Patients in CMB305 Study - Analyst Blog
11:14AM  Europe pushes back verdict on Bristol immune system cancer drug Reuters
08:49AM  Europe postpones decision on Bristol immune system cancer drug Reuters
08:00AM  Merck to Hold First-Quarter 2015 Sales and Earnings Conference Call on April 28 Business Wire
Mar-26-15 07:08PM  Two Experimental Ebola Vaccines Show Promise at The Wall Street Journal
03:12PM  Pressure's On Senate To Pass 'Doc Fix' In Latest Blow To Fee-For-Service Medicine at Forbes
02:50PM  MassBio panel tackles perils of drugs for bioterrorism and superbugs at bizjournals.com
08:55AM  Merck in $10B Buyback; Keytruda Tops Melanoma Study - Analyst Blog
08:30AM  Merck Announces Collaboration with the American Diabetes Association to Educate Adults with Diabetes About Increased Risk for Serious Diseases like Pneumococcal Pneumonia Business Wire
07:30AM  Flagship Ventures, After A String Of IPOs, Gets $537M To Build More Biotech Startups at Forbes
12:06AM  Mercks Self-Medication Is Welcome at The Wall Street Journal
Mar-25-15 06:00PM  Cramer: Nasdaq's griddle too hot
05:20PM  Ligand Pharmaceuticals: Biotech's Jack Of All Trades at Investor's Business Daily
04:41PM  Merck Announces New $10 Billion Share Repurchase Program at noodls
03:45PM  Superconductor Technologies, Inc. (SCON), Pfizer Inc. (PFE), ACADIA Pharmaceuticals Inc. (ACAD): Sabby Capitals Latest Moves in Healthcare Sector at Insider Monkey
03:33PM  Stocks plunge; Dow off 250 points, Nasdaq drops 2% at CNBC
03:00PM  Merck's Self-Medication Is Welcome at The Wall Street Journal
11:33AM  Jim Cramer Sees American Express Unable to Challenge Visa, MasterCard at TheStreet
11:10AM  4 Top-Ranked Health Care ETFs for a Healthy Portfolio - ETF News And Commentary
10:57AM  Guinea starts testing Merck vaccine in Ebola hotspots
10:18AM  Merck increases share buyback plan
09:48AM  Merck (MRK) Stock Gains Today on Share Repurchase at TheStreet
09:24AM  Cramer's Mad Dash: AXP & MRK
09:18AM  Morning Movers: Kraft Soars on Heinz Merger; Tesla Tumbles at Barrons.com
07:58AM  Early movers: KRFT, TSLA, AXP, AZO, FB, SONC & more at CNBC
Mar-24-15 05:36PM  Merck board OKs additional $10 billion stock buyback plan
05:31PM  Sonic shares rise after results top Street estimates at MarketWatch
05:24PM  Merck increases share buyback program by $10 bln
05:09PM  Merck's stock gains after new $10 billion stock repurchase program announced at MarketWatch
05:00PM  Merck Announces New $10 Billion Share Repurchase Program Business Wire
03:33PM  Merck halts study in light of melanoma drugs success at Fortune
12:47PM  Agenus Boosted by Big Pharma Deals at Barrons.com
10:59AM  Merck (MRK) Stock Gains Today on Positive Phase III Melanoma Treatment Study Results at TheStreet
10:49AM  Stocks Off To A Twitchy Start; Netflix, Twitter, Merck Surge at Investor's Business Daily
10:37AM  Merck's Keytruda Bests Yervoy In Early Melanoma at Investor's Business Daily
10:29AM  Will pharma rally continue?
10:00AM  Merck says melanoma drug meets goal; study halted
09:53AM  Stocks turn positive on strong housing number at CNBC
09:19AM  Merck's Keytruda Meets Study Goals as Advanced Melanoma Treatment at The Wall Street Journal
08:52AM  Study of Merck melanoma drug halted after survival prolonged
08:30AM  Mercks Pivotal KEYNOTE-006 Study in First-Line Treatment for Advanced Melanoma Met Co-Primary Endpoints and Will be Stopped Early Business Wire
Mar-23-15 02:58PM  11 Promising New Drugs Expected to Make Billions in Sales at TheStreet
12:21PM  SunTrust Names Eli Lilly, Merck, Bristol-Myers as 'Favorite' Pharma Firms
Mar-20-15 04:06PM  Farallon Capital Starts New Position in Cubist Pharmaceuticals
02:52PM  Dow 30 Stock Roundup: Cinderella Stars for Disney, Boeing Wins $713.9M CH-47 Contract - Analyst Blog
11:06AM  Viking Global Exited Its Position in AbbVie
10:02AM  Award-Winning Actress S. Epatha Merkerson and Merck Challenge African Americans with Type 2 Diabetes to Get to Their Goals PR Newswire
07:00AM  Supreme Court's Affordable Care Act Decision Might Prove A Buying Opportunity at Morningstar
05:40AM  Biogen Drug Could Inspire New Hope For Alzheimer's Treatments at Forbes
Mar-19-15 04:00PM  Stocks close mixed as Street eyes Fed; Facebook boosts Nasdaq at CNBC
Mar-18-15 09:05PM  Understanding Johnson & Johnsons Ownership Structure
05:05PM  Where Does Johnson & Johnson Stand in the Industry?
04:19PM  New Data Investigating Mercks KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer and Mesothelioma to Be Presented in Clinical Trials Plenary Session at AACR 2015 Business Wire
04:01PM  The 4 Stocks That Boosted the DJIA on Wednesday at 24/7 Wall St.
02:36PM  4 Biotech Reports This Month That Could Move Stocks at Investor's Business Daily
11:05AM  What Risks Does Johnson & Johnson Face?
09:44AM  Oculus Innovative Sciences Banking Millions on Ruthigen-Pulmatrix Merger
09:32AM  Tekmira Pharmaceuticals Corp (TKMR): QVT Financials New Holding and Two Other Healthcare Picks at Insider Monkey
Mar-17-15 04:41PM  Apple still buyback king as repurchases overall slow down at MarketWatch
03:28PM  Gilead Sciences: How Big a Threat is Merck? at Barrons.com
12:45PM  Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
12:45PM  Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
10:30AM  Merck Reports Encouraging Data from Cardiovascular Study - Analyst Blog
05:36AM  Merck KGaA places $4 bln bond to fund Sigma-Aldrich deal Reuters
Mar-16-15 06:00PM  Making Money With Charles Payne: 03/16/15 at Fox Business
04:45PM  Merck's Sugammadex Faces Setback, FDA Delays Meeting - Analyst Blog
03:30PM  New Analysis from Investigational IMPROVE-IT Study Shows VYTORIN® (ezetimibe/simvastatin) Reduced Total (Initial and Recurrent) Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes Business Wire
03:06PM  What Were Johnson & Johnsons Outstanding Expenses?
03:01PM  Amgen: Looking for a Wild Card at Barrons.com
12:52PM  Health Care ETFs Remain Sturdy ETF Trends
11:05AM  Johnson & Johnsons Revenue Stream Increased in 2014
Mar-13-15 05:53PM  Merck surgery drug sugammadex dealt another setback
05:25PM  [$$] FDA Delay for Merck Surgery Drug at The Wall Street Journal
05:10PM  FDA delays meeting on Merck's surgery drug at MarketWatch
04:37PM  Merck expects to be denied approval for sugammadex injection again Reuters
04:02PM  Merck Provides Regulatory Update on Investigational Medicine Sugammadex Injection Business Wire
04:00PM  Stocks close lower, with Dow off triple digits on dollar surge at CNBC
Mar-12-15 06:11PM  Illumina Partners Merck KGaA to Develop Precision Medicine - Analyst Blog
11:08AM  The Silver Lining In Big Pharma Layoffs And Site Closures? A Redistribution Of Talent And Resources at Forbes
11:06AM  Analyzing Johnson & Johnsons Three Main Business Segments
Mar-11-15 05:01PM  New Report From The NEJM On Clinical Trial Reporting Further Tarnishes Biopharma's Image at Forbes
10:45AM  U.K. Regulators Grant Early Access to Merck Skin Cancer Drug, but Where Is Northwest Bio? at TheStreet
09:40AM  4 Top Pharmaceutical Stocks to Buy for Market Safety at 24/7 Wall St.
03:38AM  Merck cancer drug is first approved under UK early access scheme Reuters - UK Focus
03:38AM  Merck cancer drug is first approved under UK early access scheme Reuters
Mar-10-15 08:01PM  KEYTRUDA® (pembrolizumab) is First Medicine to be Made Available to Patients Through U.K. Early Access to Medicines Scheme (EAMS) for Advanced Melanoma Business Wire
05:16PM  Merck KGaA to Pay $3M to Opexa for Tcelna Study - Analyst Blog
02:35PM  Tetraphase looks to double its cash with stock offering at bizjournals.com
08:00AM  Merck to Present at the Barclays Global Healthcare Conference Business Wire
07:05AM  US specialty drug spending trends in 2015 CNBC
07:04AM  Prescription drug prices rising: Report CNBC
Mar-09-15 12:20AM  Comings & Goings: News Digest at The Wall Street Journal
Mar-08-15 08:17PM  Comings & Goings: News Digest at The Wall Street Journal
Mar-06-15 03:10PM  Merck Inks Deal with Eisai for Cancer Combo Therapy - Analyst Blog Zacks
01:43PM  Layoffs at Cubist come amid a steady flow of senior execs out of Merck at bizjournals.com
12:20PM  After Apple Added to DJIA, at Least 3 More Dow Stocks Could Get Booted at 24/7 Wall St.
Mar-05-15 05:19PM  This sector could be the best bet this year Talking Numbers
03:21PM  Hedge Funds Are Crazy About These Five Dow Jones Dividend Leaders at Insider Monkey
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; antidepressants; ophthalmic and cholesterol modification products; non-sedating antihistamine; and vaginal contraceptive implants. In addition, the company provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; to treat brain tumors and melanoma; to prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers animal health products, including antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics for, and vaccines against bacterial and viral disease in fish. Additionally, the company provides companion animal products, such as diabetes mellitus treatment drugs and vaccines for dogs and cats; ointments for acute and chronic otitis; anthelmintic products; chewable tablets to kill fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. The company serves drug wholesalers and retailers, hospitals, government entities and agencies, physicians, physician distributors, veterinarians, distributors, and animal producers, as well as managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FRAZIER KENNETH CChairman, President & CEOFeb 18Option Exercise31.847,082225,491358,564Feb 18 04:51 PM
FRAZIER KENNETH CChairman, President & CEOFeb 18Sale58.675,164302,959353,400Feb 18 04:51 PM
Deese Willie AExe V-P & Pres. MMDFeb 11Option Exercise40.44135,8645,494,524242,094Feb 11 02:19 PM
Deese Willie AExe V-P & Pres. MMDFeb 11Sale58.56135,8647,956,372106,230Feb 11 02:19 PM
WENDELL PETER CDirectorFeb 09Option Exercise33.835,000169,1506,000Feb 09 03:24 PM
WENDELL PETER CDirectorFeb 09Sale58.765,000293,7971,000Feb 09 03:24 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 15Option Exercise41.1874,2003,055,57874,200Jan 15 03:55 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 15Sale62.4874,2004,636,2240Jan 15 03:55 PM
FRAZIER KENNETH CChairman, President & CEOJan 09Option Exercise34.2012,874440,240360,322Jan 09 02:44 PM
FRAZIER KENNETH CChairman, President & CEOJan 09Sale62.478,840552,267351,482Jan 09 02:44 PM
FRAZIER KENNETH CChairman, President & CEODec 10Option Exercise34.2012,874440,240357,294Dec 10 05:59 PM
FRAZIER KENNETH CChairman, President & CEODec 10Sale60.009,846590,760347,448Dec 10 05:59 PM
Kuhlik Bruce NExe V-P & Gen CounselDec 08Option Exercise51.0250,0002,551,000178,467Dec 08 06:55 PM
Kuhlik Bruce NExe V-P & Gen CounselDec 08Sale62.0050,0003,100,000128,467Dec 08 06:55 PM
LAZARUS ROCHELLE BDirectorNov 26Option Exercise34.1410,000341,35014,595Nov 26 12:40 PM
LAZARUS ROCHELLE BDirectorNov 26Sale59.6310,000596,3004,595Nov 26 12:40 PM
WEEKS WENDELL PDirectorNov 24Option Exercise33.835,000169,1505,100Nov 25 07:08 PM
WEEKS WENDELL PDirectorNov 24Sale59.135,000295,663100Nov 25 07:08 PM
FRAZIER KENNETH CChairman, President & CEONov 10Option Exercise34.2012,875440,272354,420Nov 10 04:36 PM
FRAZIER KENNETH CChairman, President & CEONov 10Sale57.9810,000579,784344,420Nov 10 04:36 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthNov 02Option Exercise0.004,38704,387Nov 03 04:46 PM
FRAZIER KENNETH CChairman, President & CEOOct 10Option Exercise34.2012,875440,272351,440Oct 14 09:05 AM
FRAZIER KENNETH CChairman, President & CEOOct 10Sale59.739,895591,033341,545Oct 14 09:05 AM
FRAZIER KENNETH CChairman, President & CEOSep 10Option Exercise34.2012,875440,272348,379Sep 10 01:53 PM
FRAZIER KENNETH CChairman, President & CEOSep 10Sale60.489,814593,592338,565Sep 10 01:53 PM
FRAZIER KENNETH CChairman, President & CEOAug 11Option Exercise34.2012,875440,272345,562Aug 12 09:01 AM
FRAZIER KENNETH CChairman, President & CEOAug 11Sale57.0010,058573,306335,504Aug 12 09:01 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerAug 04Option Exercise45.3823,4001,061,82042,844Aug 05 09:56 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerAug 04Sale56.6428,6691,623,72014,175Aug 05 09:56 AM
REPRESAS CARLOS EDirectorAug 01Option Exercise35.195,000175,9505,500Aug 05 10:16 AM
FRAZIER KENNETH CChairman, President & CEOJul 10Option Exercise34.2012,876440,307351,474Jul 10 03:47 PM
FRAZIER KENNETH CChairman, President & CEOJul 10Sale58.039,987579,545341,487Jul 10 03:47 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 07Option Exercise30.01180,0475,403,278273,611Jul 08 02:16 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 07Sale59.16180,04710,650,93293,564Jul 08 02:16 PM
Deese Willie AExe V-P & Pres. MMDJun 27Option Exercise27.8572,2902,013,164178,512Jun 30 04:23 PM
Deese Willie AExe V-P & Pres. MMDJun 27Sale58.2672,2904,211,254106,222Jun 30 04:23 PM
Schechter Adam HEVP & Pres-Global Human HealthMay 14Sale55.9110,527588,5840May 14 02:48 PM
FRAZIER KENNETH CChairman, President & CEOMay 09Option Exercise34.2012,876440,307345,927May 13 03:56 PM
FRAZIER KENNETH CChairman, President & CEOMay 09Sale55.0010,220562,100335,707May 13 03:56 PM
Schechter Adam HEVP & Pres-Global Human HealthMay 04Option Exercise0.0019,147019,147May 06 04:03 PM
Golestani ClarkEVP & Chief Info OfficerMay 04Option Exercise0.002,05109,278May 06 04:02 PM
GRADDICK WEIR MIRIAN MExe V-P, HRMay 04Option Exercise0.009,300098,387May 06 04:02 PM
Heller Bridgette PExe.VP & Pres.Con.Hlth.CareMay 04Option Exercise0.005,470038,311May 06 04:02 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 04Option Exercise0.004,240011,999May 06 04:02 PM
Kuhlik Bruce NExe V-P & Gen CounselMay 04Option Exercise0.009,8470132,660May 06 04:02 PM
Rosenblatt MichaelExec V-P & Chief Med OfficerMay 04Option Exercise0.004,103026,720May 06 04:02 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 04Option Exercise0.004,103020,828May 06 04:01 PM
Deese Willie AExe V-P & Pres. MMDMay 04Option Exercise0.007,6590109,671May 06 04:01 PM
FRAZIER KENNETH CChairman, President & CEOMay 04Option Exercise0.0041,0280351,522May 06 04:01 PM
HARRISON WILLIAM B JRDirectorApr 25Option Exercise47.235,000236,1506,400Apr 29 11:36 AM
FRAZIER KENNETH CChairman, President & CEOApr 10Option Exercise34.2012,876440,307320,541Apr 11 09:53 AM
FRAZIER KENNETH CChairman, President & CEOApr 10Sale57.2410,047575,108310,494Apr 11 09:53 AM
Kuhlik Bruce NExe V-P & Gen CounselApr 04Option Exercise39.90145,2255,794,929267,070Apr 04 05:07 PM
Kuhlik Bruce NExe V-P & Gen CounselApr 04Sale56.43145,2258,195,164121,845Apr 04 05:07 PM